All In Biotech

Free tool

FAERS Monitor: Truxima

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761088 or its brand name (Truxima, Rituximab-Abbs). Reports on generic versions are filed under their own applications.

Reports

5,105

Serious

3,752

73% of reports

Hospitalization

1,394

Death reported

537

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use2,347
  • intentional product use issue347
  • hypertension295
  • pain272
  • rheumatoid arthritis264
  • fatigue261
  • infusion related reaction251
  • intentional dose omission248
  • dyspnoea246
  • pyrexia242
  • rash234
  • drug ineffective232
  • nausea225
  • headache216
  • death208

Reports by year received

View as table
YearReports
20174
201891
2019342
2020556
2021820
20221,093
2023749
2024598
2025527
2026325

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,054 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intentional dose omissionSignal24836.132.08,378
intentional product use issueSignal34716.414.84,997
infusion related reactionSignal25115.713.93,427
off label useSignal2,34711.110.722,363
rheumatoid arthritisSignal2649.68.52,032
hypertensionSignal2955.75.11,162
pyrexiaSignal2422.92.5300
rashSignal2342.22.0157
pain2721.81.6104
dyspnoea2461.81.687
headache2161.41.227
fatigue2611.41.228
nausea2251.21.06
death2081.00.90
drug ineffective2320.70.625

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.